Streptavidin in antibody pretargeting. Comparison of a recombinant streptavidin with two streptavidin mutant proteins and two commercially available streptavidin proteins

被引:23
作者
Wilbur, DS
Stayton, PS
To, R
Buhler, KR
Klumb, LA
Hamlin, DK
Stray, JE
Vessella, RL
机构
[1] Univ Washington, Dept Radiat Oncol, Seattle, WA 98103 USA
[2] Univ Washington, Dept Bioengn, Seattle, WA 98103 USA
[3] Univ Washington, Dept Urol, Seattle, WA 98103 USA
关键词
D O I
10.1021/bc970152s
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In this investigation, a comparison of wild type recombinant streptavidin (r-SAv) with two genetically engineered mutant r-SAv proteins was undertaken. The investigation also included a comparison of the r-SAv with two streptavidin (SAv) proteins from commercial sources. In vitro characterization of the SAv proteins was conducted by HPLC, SDS-PAGE, IEF, and electrospray mass spectral analyses. All SAv proteins studied appeared to be a single species by size exclusion chromatography (HPLC) and SDS-PAGE analyses, but multiple species were noted in the IEF and MS analyses. In vivo comparisons of the SAV proteins were accomplished with dual isotope-labeled SAv in athymic mice. In an initial experiment, tissue localization of r-[I-131]SAv directly radiolabeled using chloramine-T was compared with r-SAv radiolabeled with the N-hydroxysuccinimidyl p-iodobenzoate conjugate ([I-125]-PIB), a radioiodination reagent that has been shown to result in iodine-labeled proteins which are stable to in vivo deiodination. The data obtained indicated that there is little difference in the distribution (except kidney localization) when r-SAv labeled by the two methods. Data obtained from comparison of r-[I-131]SAv with a disulfide-stabilized r-SAv mutant (r-SAv-H127C), a C-terminal cysteine-containing r-SAv mutant (r-[I-125]SAv-S139C), and two I-125-labeled SAv proteins obtained from commercial sources indicated that their distributions were quite similar, except the kidney concentrations were generally lower than that of r-[I-131]SAv. On the basis of the similar distributions of the SAv proteins studied, it appears that the r-SAv mutants may be interchanged for the (wild type) r-SAv in pretargeting studies. Further, the similarity of distributions with two commercially available SAv proteins suggests that the results obtained in our studies and those of other groups may be directly compared (with consideration of animal model, sacrifice time, etc.).
引用
收藏
页码:100 / 107
页数:8
相关论文
共 51 条
[1]   MOLECULAR-CLONING AND NUCLEOTIDE-SEQUENCE OF THE STREPTAVIDIN GENE [J].
ARGARANA, CE ;
KUNTZ, ID ;
BIRKEN, S ;
AXEL, R ;
CANTOR, CR .
NUCLEIC ACIDS RESEARCH, 1986, 14 (04) :1871-1882
[2]  
Axworthy DB, 1994, J IMMUNOTHER, V16, P158
[3]   AN IMPROVED METHOD FOR THE SINGLE-STEP PURIFICATION OF STREPTAVIDIN [J].
BAYER, EA ;
BENHUR, H ;
GITLIN, G ;
WILCHEK, M .
JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, 1986, 13 (02) :103-112
[4]   POSTSECRETORY MODIFICATIONS OF STREPTAVIDIN [J].
BAYER, EA ;
BENHUR, H ;
HILLER, Y ;
WILCHEK, M .
BIOCHEMICAL JOURNAL, 1989, 259 (02) :369-376
[5]   SITE-DIRECTED MUTAGENESIS STUDIES OF THE HIGH-AFFINITY STREPTAVIDIN-BIOTIN COMPLEX - CONTRIBUTIONS OF TRYPTOPHAN RESIDUE-79, RESIDUE-108, AND RESIDUE-120 [J].
CHILKOTI, A ;
TAN, PH ;
STAYTON, PS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) :1754-1758
[6]   ENGINEERED CHIMERIC STREPTAVIDIN TETRAMERS AS NOVEL TOOLS FOR BIOSEPARATIONS AND DRUG-DELIVERY [J].
CHILKOTI, A ;
SCHWARTZ, BL ;
SMITH, RD ;
LONG, CJ ;
STAYTON, PS .
BIO-TECHNOLOGY, 1995, 13 (11) :1198-1204
[7]  
DELROSARIO RB, 1993, J NUCL MED, V34, P1147
[8]  
DELROSARIO RB, 1990, CANCER RES, V50, P804
[9]  
DIAMANDIS EP, 1991, CLIN CHEM, V37, P625
[10]   A NATIVE, AFFINITY-BASED PROTEIN BLOT FOR THE ANALYSIS OF STREPTAVIDIN HETEROGENEITY - CONSEQUENCES FOR THE SPECIFICITY OF STREPTAVIDIN MEDIATED BINDING ASSAYS [J].
DITTMER, J ;
DITTMER, A ;
DELLABRUNA, R ;
KASCHE, V .
ELECTROPHORESIS, 1989, 10 (11) :762-765